NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

Drugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...

Novo Nordisk (NYSE: NVO) stock slipped 1.7% through 12:10 a.m. ET Monday on a pair of news items with which investors seem ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

StockNews.com downgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a strong-buy rating to a buy rating in a ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) and reminds investors of the ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that market experts are talking about these days. Piper Sandler’s Chief Market ...